ByteDance Raises $1.5 Billion for Its AI Pharma Company: A Bold Leap by a Tech Giant, or a Prelude to Change in the Pharmaceutical Industry?
Hello everyone, I'm your financial journalist. Today, we have an incredibly interesting story to share: Anew Labs, an AI pharmaceutical company under ByteDance, has just completed its first round of external financing, valued at a staggering $1.5 billion (approximately over 10 billion RMB).
You might be wondering, how did ByteDance, known for its short-video platform, suddenly get into the pharmaceutical business? And why would they separate this business and seek investment from external parties? Behind this move lies a significant collision between tech giants and the traditional pharmaceutical industry.
To make this complex financial news easier to understand, I've broken it down into five key points, explaining the logic, risks, and opportunities involved in plain language.
---
1. Why Did ByteDance Decide to Separate Anew Labs?
First, let's clarify Anew Labs' new status. It is no longer just an internal lab or project team at ByteDance; it is now an independent company with external shareholders.
- The equity structure is intriguing: Although top investors like Sequoia China (HSG), IDG, and 5Y Capital have joined in, ByteDance still holds 56% of the shares, making it the majority owner. This means ByteDance retains control while also obtaining $290 million in new funding through the financing.
- The reason for independence: The article explains it clearly: AI in pharmaceuticals cannot be limited to theoretical calculations. Internet products like TikTok can be updated weekly; if something goes wrong, they can be fixed immediately. However, drug development is a slow, capital-intensive process with a high failure rate. There are numerous hurdles between the lab and patient use—preclinical trials, Phase I, Phase II, Phase III clinical trials, and regulatory approvals. This type of business requires specialized pharmaceutical capital, talent, and an independent equity structure to handle potential future listings or acquisitions. If Anew Labs remained under ByteDance's umbrella, it would be difficult to attract professional funds focused on pharmaceuticals, and it would be less flexible in managing drug rights.
In simple terms: It's like a chef (ByteDance) who realizes that cooking is too complex, costly, and time-consuming, so they set up their own restaurant (Anew Labs). The chef (ByteDance) still owns the restaurant, but they need professional investors (external shareholders) to renovate, purchase ingredients, and operate according to the restaurant's (pharmaceutical R&D) logic, not the home cooking logic.
---
2. The New Approach to AI in Pharmaceuticals: From “Providing Tools” to “Developing Drugs Themselves”
In the past few years, AI pharmaceutical companies mainly acted as providers of tools—they offered powerful AI algorithms to help companies quickly screen molecules, and pharmaceutical companies paid to use them. However, the trend is changing. Companies like Anew Labs, Isomorphic Labs (owned by Google), and InSilico Medicine are now taking the initiative to develop their own drug pipelines.
- Anew Labs' actions: Their website lists specific drug projects, such as IL17 and IL4R, and they have already begun preparing applications for clinical trials (IND submissions). This indicates that they are no longer just providing tools but are actually developing drugs.
- Industry consensus: Google’s Isomorphic Labs raised $2.1 billion to upgrade its AI engine and develop its own drugs; InSilico Medicine builds platforms and licenses its technology to other companies for joint development.
- Why this shift? If they only sell software, their profit comes from service fees. But if they own the drug rights, they can earn billions or even tens of billions in sales royalties if the drug is successful. The potential for returns is huge, but so are the risks if the drug fails.
In simple terms: Previously, AI companies were like arms dealers, supplying pharmaceutical companies with “scopes” (AI algorithms), while the companies did the actual research and development. Now, AI companies believe they can do it all themselves, building their own teams and developing drugs. If they succeed, the profits go to them; if not, the losses are also theirs.
---
3. Can AI Really Save Lives? The Sweet Spots and Harsh Reality Behind the Data
Many people question whether AI is just hype. Can it really accelerate drug development? The article cites data from IQVIA and Nature Reviews Drug Discovery, offering a more objective answer: AI is useful in the early stages but still depends on other factors in the later stages.
- Good news (early efficiency): AI is powerful in the early stages of drug development, helping to quickly screen potential candidates from a vast number of molecules and eliminate many doomed approaches. Data shows that emerging biotech companies using AI have a Phase I clinical success rate of about 75%, which is higher than those without AI.
- Bad news (later stages are still challenging): The success rates for Phase II clinical trials are similar for both AI and non-AI projects. By Phase III clinical trials, the sample sizes are too small to compare effectively. The core issue is that drugs still have to meet traditional biological requirements. AI can help find potentially effective molecules faster, but it cannot guarantee safety and efficacy.
- Time difference: AI provides results quickly (weeks/months), but clinical validation takes years. While AI speeds up the initial screening, the later stages require more money for testing, production, and patient recruitment.
In simple terms: AI is like a highly efficient “preliminary interviewer” that can review ten thousand resumes in a second and select 100 candidates. However, whether these candidates are suitable (safe and effective in humans) still requires a long trial period.
---
4. What Does the $1.5 Billion Valuation Mean?
The $1.5 billion valuation might sound impressive, but for the pharmaceutical industry, it represents a dynamic and uncertain “market benchmark.”
- Valuation doesn’t equal assets: This amount is not based on the sum of the company’s assets; it reflects the market’s expectations for its future success.
- Critical milestones determine success: Anew Labs’ most advanced project, IL17, is still in the pre-clinical trial stage. The pharmaceutical industry has a notorious “valley of death”—each step from the lab to patient trials to market launch is a competitive elimination process. If IL17 gets clinical approval, the valuation may rise; if it fails, it may fall. Additionally, AI technology is rapidly becoming more widespread. If other companies also develop useful AI tools, Anew Labs’ technological uniqueness will decrease, weakening its valuation.
In simple terms: The $1.5 billion is like a “promissory note” representing the potential for Anew Labs to develop successful drugs. Whether this note will be cashed in depends on several key factors:
1. Can IL17 obtain clinical approval?
2. Are the clinical trial results promising?
3. Can they find partners to share the risks?
4. Will they have enough funds to sustain the next round of development?
If any of these steps fail, the valuation could significantly decrease.
---
5. Can Big Tech Break the “Double Ten Law”?
Finally, let’s consider the harsh reality of the innovative pharmaceutical industry:
- The Double Ten Law: It takes an average of 10 years from research and development to market launch, and the cost is around $1.0 billion (with Deloitte reporting that late-stage development costs have risen to about $2.67 billion).
- Only 10% of drugs succeed: Less than 10% of drugs make it to market.
With ByteDance’s support in terms of computing power, funding, and talent, can Anew Labs break this law?
- Advantages: ByteDance has a strong financial foundation, allowing it to support the long-term development process. Its AI models can be continuously upgraded, keeping it technologically ahead. It also has teams in Shanghai, San Francisco, and Singapore, leveraging global resources.
- Disadvantages/Risks: There are significant cultural differences between the tech (fast iteration, user growth) and pharmaceutical (rigorousness, compliance, long-term focus) worlds. Competition is fierce, with companies like Google, InSilico Medicine, and Recursion also in the field. Additionally, they must overcome regulatory barriers set by health authorities (e.g., FDA, NMPA).
In simple terms: ByteDance provides Anew Labs with a powerful platform, but the pharmaceutical industry is a challenging marathon. Despite the fast car (ByteDance’s resources), the muddy roads (clinical trials and regulatory approvals) still test the team’s endurance.
---
Summary: What Does Anew Labs Represent?
The emergence of Anew Labs marks a transition from conceptual hype to practical action in the field of “AI + pharmaceuticals.”
1. It demonstrates that tech giants can cross industries and directly participate in high-risk, high-return biopharmaceutical activities.
2. It reveals a new business model where “AI platforms + proprietary pipelines + external collaborations” will become standard for future biotech companies.
3. It reminds us to remain cautious: The $1.5 billion valuation is just the starting point, not the end goal. AI can speed up the discovery process but cannot replace the rigorous clinical validation required.
For the general public, following Anew Labs is about watching how technology can transform the healthcare industry. If successful, it could lead to innovative biotech solutions and faster drug approvals, benefiting patients. If not, it will provide valuable lessons for the industry.
In any case, this AI pharmaceutical experiment led by ByteDance is just beginning. What we need to watch closely are not just the financing news but the clinical data and regulatory progress, as these will determine the company’s fate.
Thank you for listening!